Chennai, Apr 22 (UNI) In its fight against COVID, the Chennai-
based pharma manufacturer Apex Laboratories Private Limited
today said it has revceived the approval for Antiviral drug Clevira
as a supporting measure for mild to moderate condition of COVID.
The company has received approval from the Union Ministry of
AYUSH for Clevira as an additional supporting measure, making
it first of its kind approval in India through various stages of scrutiny
at CCRAS (The Central Council for Research in Ayurvedic Sciences)
and Inter-Disciplinary Technical Review Committee (ITRC) a
12-member technical committee constituted by Ministry of AYUSH
and headed by Dr.S.K.Maulik Former Professor Department of
Pharmacology AIIMS.
Clevira is the brain child of apex’s R and D Center based on
proven scientific evidence and was launched in Indian market
during the recent outbreak of dengue epidemic and associated
mortality in 2017.
Clevira is extensively studied for its safety in animal model
(Wistar rats) and efficacy in human subjects in Phase II and
III clinical trials.
It is an approved antiviral formulation for treatment of various
viral infections including viral fever associated with or without
thrombocytopenia, besides it has proven for its efficacy as
Analgesic, Antipyretic and reversal of thrombocytopenia apart
from its Antiviral property, according to a release here.
A phase III Clinical trial was carried out in Government Medical
College Omandurar Government Estate and the outcomes revealed
that Clevira has shown 86 per cent recovery rate on fifth day of
treatment in mild to moderate COVID-19.
The release said 100 per cent recovery rate was noticed on 10th
day of treatment and clinical recovery from all signs and symptoms
was registered in four days.
Clevira is proven to be safe on Kidney and Liver parameters.
The study outcomes were placed before the Tamil Nadu Government,
Indian Council of Medical Research (ICMR) and Ministry of AYUSH
in 2020.
After various stages of scrutiny and deliberations before various
technical review committees, Ministry of AYUSH regulators have
granted approval for Clevira as a supporting measure for mild
to moderate COVID cases.
Clevira is effective when taken orally and the dosage is one tablet
twice daily after food for 14 days.
UNI GV 1445